Radius Health Inc banner

Radius Health Inc
NASDAQ:RDUS

Watchlist Manager
Radius Health Inc Logo
Radius Health Inc
NASDAQ:RDUS
Watchlist
Price: 30 USD Market Closed
Market Cap: $847.8m

Radius Health Inc
Goodwill

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Radius Health Inc
Goodwill Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Goodwill CAGR 3Y CAGR 5Y CAGR 10Y
Radius Health Inc
NASDAQ:RDUS
Goodwill
$13.1m
CAGR 3-Years
-63%
CAGR 5-Years
-40%
CAGR 10-Years
-23%
Abbvie Inc
NYSE:ABBV
Goodwill
$35.6B
CAGR 3-Years
4%
CAGR 5-Years
-4%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Goodwill
$8.3B
CAGR 3-Years
0%
CAGR 5-Years
15%
CAGR 10-Years
22%
Amgen Inc
NASDAQ:AMGN
Goodwill
$18.7B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Goodwill
$1.5B
CAGR 3-Years
12%
CAGR 5-Years
9%
CAGR 10-Years
41%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Goodwill
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Radius Health Inc
Glance View

Market Cap
847.8m USD
Industry
Biotechnology

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company is headquartered in Boston, Massachusetts and currently employs 293 full-time employees. The company went IPO on 2014-06-06. The firm is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The firm also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

RDUS Intrinsic Value
54.23 USD
Undervaluation 45%
Intrinsic Value
Price

See Also

What is Radius Health Inc's Goodwill?
Goodwill
13.1m USD

Based on the financial report for May 31, 2025, Radius Health Inc's Goodwill amounts to 13.1m USD.

What is Radius Health Inc's Goodwill growth rate?
Goodwill CAGR 10Y
-23%

Over the last year, the Goodwill growth was 0%. The average annual Goodwill growth rates for Radius Health Inc have been -63% over the past three years , -40% over the past five years , and -23% over the past ten years .

Back to Top